Nanoform

Activities: Drug Delivery Research & Development

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing attrition in clinical trials and on enhancing drug molecules’ formulation performance through its nanoforming services. Nanoform’s capabilities include GMP manufacturing and span the small to large molecule development space. The company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications.

Trending Articles

  1. Serialisation and data connectivity: Part I The new wrinkle in your supply chain
  2. Liquid versus lyophilised: overcoming the challenges of high-potency formulations in modern pharma Formulating highly potent (HiPo) compounds presents unique challenges that require expertise and precise decision making
  3. SGS’s Shanghai Health Science laboratory completes US FDA inspection with zero 483 observations SGS, the world’s leading testing, inspection and certification company, has set a new benchmark for third-party pharmaceutical testing laboratories in China following an...
  4. Lonza completes acquisition of large-scale biologics site in Vacaville (US) from Roche Acquisition extends Lonza’s US Biologics footprint with a significant presence on the West Coast, complementing its existing global manufacturing network
  5. SRI International awarded US$19.8m National Cancer Institute contract for PREVENT Cancer programme Will conduct preclinical studies to assess the efficacy of specific compounds or vaccines for preventing invasive-cancer development

Upcoming event

ISCC

15-18 October 2024 | Conference | Milan, Italy See all

Related Content

Research & Development

Nanoform and Takeda team up to advance plasma-derived therapy development

The collaboration will aim to develop plasma-derived therapeutics and accelerate the movement of potential medicines into the clinic
Research & Development

Apalutamide study demonstrates the advantages of nanoforming for cancer treatment

Nanoform’s technology delivers some of the world’s smallest nanoparticles at clinical and commercial scale
Research & Development

Nanoform announces clinical results for Enzalutamide cancer drug

The nanotechnology expert has announced promising clinical results for its Enzalutamide drug to treat prostate cancer
Research & Development

Nanoform commenced relative bioavailability study of nanotechnology enhanced enzalutamide

Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilising Nanoform’s platform technologies
Ingredients

Nanoform grants Global STARMAP AI License to AstraZeneca

Nanoform Finland, an innovative nanoparticle medicine-enabling company has announced that it has granted AstraZeneca Plc a global online STARMAP licence
Drug Delivery

Nanoformed TargTex oncology drug candidate TTX101 receives FDA Orphan Drug Designation

Nanoform Finland Plc (Nasdaq Helsinki NANOFH; Nasdaq Stockholm NANOFS), an innovative nanoparticle medicine enabling company, announced its customer TargTex S.A. has been granted Orphan Drug Designation by the FDA for its nanoformed drug candidate TTX101 to be used in patients with malignant gliomas
Drug Delivery

Nanoform and Celanese demonstrate enhanced drug delivery through the power of smaller implants

The API nanoparticles produced through Nanoform’s CESS technology and the Celanese VitalDose EVA copolymer delivery technology have the potential to enable enhanced sustained release
Subscribe now